RhumbLine Advisers’s Insmed INSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$29.1M Buy
272,715
+100
+0% +$12.1K 0.02% 582
2026
Q1
$44.6M Buy
272,615
+4,289
+2% +$659K 0.04% 389
2025
Q4
$46.7M Buy
268,326
+55,423
+26% +$10.1M 0.04% 374
2025
Q3
$30.7M Buy
212,903
+4,558
+2% +$558K 0.02% 543
2025
Q2
$21M Sell
208,345
-95,212
-31% -$7.28M 0.02% 682
2025
Q1
$23.2M Buy
303,557
+15,220
+5% +$1.16M 0.02% 612
2024
Q4
$19.9M Buy
288,337
+25,292
+10% +$1.82M 0.02% 698
2024
Q3
$19.2M Buy
263,045
+26,518
+11% +$1.96M 0.02% 740
2024
Q2
$15.8M Buy
236,527
+28,865
+14% +$1.12M 0.01% 800
2024
Q1
$5.63M Buy
207,662
+3,966
+2% +$111K 0.01% 1351
2023
Q4
$6.31M Buy
203,696
+6,053
+3% +$157K 0.01% 1278
2023
Q3
$4.99M Buy
197,643
+4,081
+2% +$93.3K 0.01% 1346
2023
Q2
$4.08M Buy
193,562
+5,890
+3% +$112K ﹤0.01% 1498
2023
Q1
$3.2M Buy
187,672
+5,307
+3% +$103K ﹤0.01% 1570
2022
Q4
$3.64M Buy
182,365
+22,254
+14% +$430K ﹤0.01% 1463
2022
Q3
$3.45M Buy
160,111
+13,872
+9% +$333K 0.01% 1448
2022
Q2
$2.88M Buy
146,239
+18,462
+14% +$387K ﹤0.01% 1561
2022
Q1
$3M Buy
127,777
+5,723
+5% +$133K ﹤0.01% 1600
2021
Q4
$3.33M Sell
122,054
-408
-0.3% -$11.7K ﹤0.01% 1601
2021
Q3
$3.37M Buy
122,462
+6,601
+6% +$173K ﹤0.01% 1590
2021
Q2
$3.3M Sell
115,861
-4,469
-4% -$133K ﹤0.01% 1668
2021
Q1
$4.1M Sell
120,330
-14,436
-11% -$552K 0.01% 1522
2020
Q4
$4.49M Buy
134,766
+4,249
+3% +$155K 0.01% 1414
2020
Q3
$4.2M Sell
130,517
-29,645
-19% -$852K 0.01% 1280
2020
Q2
$4.41M Buy
160,162
+32,190
+25% +$763K 0.01% 1284
2020
Q1
$2.05M Buy
127,972
+2,763
+2% +$65.5K ﹤0.01% 1531
2019
Q4
$2.99M Buy
125,209
+8,380
+7% +$170K 0.01% 1568
2019
Q3
$2.06M Buy
116,829
+7,409
+7% +$143K ﹤0.01% 1729
2019
Q2
$2.8M Buy
109,420
+6,808
+7% +$190K 0.01% 1521
2019
Q1
$2.98M Sell
102,612
-120
-0.1% -$3.11K 0.01% 1478
2018
Q4
$1.35M Buy
102,732
+32,813
+47% +$524K ﹤0.01% 1871
2018
Q3
$1.41M Sell
69,919
-4,840
-6% -$109K ﹤0.01% 1840
2018
Q2
$1.77M Buy
74,759
+1,540
+2% +$39.6K ﹤0.01% 1735
2018
Q1
$1.65M Sell
73,219
-1,355
-2% -$35.7K ﹤0.01% 1710
2017
Q4
$2.33M Sell
74,574
-10,798
-13% -$319K ﹤0.01% 1538
2017
Q3
$2.66M Buy
85,372
+12,392
+17% +$236K 0.01% 1419
2017
Q2
$1.25M Sell
72,980
-502
-0.7% -$8.57K ﹤0.01% 1836
2017
Q1
$1.29M Buy
73,482
+2,533
+4% +$39.1K ﹤0.01% 1801
2016
Q4
$939K Buy
70,949
+3,608
+5% +$49.2K ﹤0.01% 1885
2016
Q3
$978K Sell
67,341
-220
-0.3% -$2.75K ﹤0.01% 1822
2016
Q2
$666K Buy
67,561
+2,745
+4% +$32K ﹤0.01% 2019
2016
Q1
$821K Buy
64,816
+5
+0% +$66 ﹤0.01% 1915
2015
Q4
$1.18M Buy
64,811
+4,735
+8% +$83.4K ﹤0.01% 1704
2015
Q3
$1.12M Buy
60,076
+1,621
+3% +$40.5K ﹤0.01% 1698
2015
Q2
$1.43M Buy
58,455
+9,250
+19% +$210K ﹤0.01% 1639
2015
Q1
$1.02M Buy
49,205
+6,975
+17% +$123K ﹤0.01% 1844
2014
Q4
$653K Buy
42,230
+3,060
+8% +$43.4K ﹤0.01% 2096
2014
Q3
$511K Buy
39,170
+3,195
+9% +$48.2K ﹤0.01% 2207
2014
Q2
$719K Buy
35,975
+4,193
+13% +$62.1K ﹤0.01% 2046
2014
Q1
$605K Sell
31,782
-1,380
-4% -$26.2K ﹤0.01% 2096
2013
Q4
$564K Buy
33,162
+2,600
+9% +$39.8K ﹤0.01% 2182
2013
Q3
$477K Buy
30,562
+5,142
+20% +$65.3K ﹤0.01% 2240
2013
Q2
$304K Buy
+25,420
New +$260K ﹤0.01% 2632

Other funds holding INSM

RhumbLine Advisers's INSM Position: Q2 2026 in Review

RhumbLine Advisers increased its Insmed (INSM) stake by 0.04% in Q2 2026, buying an estimated $12.1K and bringing the position to 272,715 shares worth $29.1M. The position accounts for 0.02% of the portfolio, ranked #582.

RhumbLine Advisers first reported a position in INSM in Q2 2013 and has held it in 53 quarters since. The position peaked at $46.7M in Q4 2025. 462 funds tracked by Wall St. Rank hold INSM as of Q2 2026.

  • RhumbLine Advisers held 272,715 shares of Insmed worth $29.1M as of Q2 2026.
  • RhumbLine Advisers bought 100 Insmed shares in Q2 2026, an estimated $12.1K.
  • Insmed made up 0.02% of RhumbLine Advisers's portfolio in Q2 2026, its #582 holding.
  • RhumbLine Advisers first reported a position in Insmed in Q2 2013 and has held it in 53 quarters since.
  • RhumbLine Advisers's Insmed position peaked at $46.7M in Q4 2025.
  • 462 funds tracked by Wall St. Rank held Insmed as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.